Royalty Pharma (RPRX) Stock Overview
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
RPRX Community Fair Values
Create NarrativeSee what 34 others think this stock is worth. Follow their fair value or set your own to get alerts.
Royalty Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.06 |
| 52 Week High | US$38.00 |
| 52 Week Low | US$24.05 |
| Beta | 0.54 |
| 1 Month Change | -2.70% |
| 3 Month Change | 10.48% |
| 1 Year Change | 25.16% |
| 3 Year Change | -13.75% |
| 5 Year Change | -13.63% |
| Change since IPO | -18.97% |
Recent News & Updates
Recent updates
Royalty Pharma: Keep Delivering, Buy Confirmed
Aug 09Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price
Jul 06
Here's Why We Think Royalty Pharma (NASDAQ:RPRX) Is Well Worth Watching
May 31Royalty Pharma: Delivering Growth With A Positive Story Ahead
Feb 13Subdued Growth No Barrier To Royalty Pharma plc (NASDAQ:RPRX) With Shares Advancing 25%
Jan 29Royalty Pharma: Key Strategic Updates To Be Priced In
Jan 15Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.22
Jan 13We Think Royalty Pharma (NASDAQ:RPRX) Can Stay On Top Of Its Debt
Dec 05Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)
Nov 13Royalty Pharma: Massive Opportunity Ahead
Nov 09Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21
Oct 14Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)
Oct 09Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
Aug 22Royalty Pharma: Busy Putting Capital To Work
Aug 11Royalty Pharma: Solid Start Of The Year, Buy Confirmed
May 11Royalty Pharma: Solid Operational Performance
Feb 19Royalty Pharma: One Of The Best Names In Pharmaceuticals
Jan 22Shareholder Returns
| RPRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.2% | 0.6% | 1.9% |
| 1Y | 25.2% | -12.6% | 17.5% |
Return vs Industry: RPRX exceeded the US Pharmaceuticals industry which returned -12.5% over the past year.
Return vs Market: RPRX exceeded the US Market which returned 16.2% over the past year.
Price Volatility
| RPRX volatility | |
|---|---|
| RPRX Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RPRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RPRX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc Fundamentals Summary
| RPRX fundamental statistics | |
|---|---|
| Market cap | US$20.98b |
| Earnings (TTM) | US$1.02b |
| Revenue (TTM) | US$2.31b |
Is RPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPRX income statement (TTM) | |
|---|---|
| Revenue | US$2.31b |
| Cost of Revenue | -US$394.65m |
| Gross Profit | US$2.70b |
| Other Expenses | US$1.68b |
| Earnings | US$1.02b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.36 |
| Gross Margin | 117.12% |
| Net Profit Margin | 44.28% |
| Debt/Equity Ratio | 84.2% |
How did RPRX perform over the long term?
See historical performance and comparisonDividends
Does RPRX pay a reliable dividends?
See RPRX dividend history and benchmarks| Royalty Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Aug 15 2025 |
| Dividend Pay Date | Sep 10 2025 |
| Days until Ex dividend | 14 days |
| Days until Dividend pay date | 12 days |
Does RPRX pay a reliable dividends?
See RPRX dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/27 18:13 |
| End of Day Share Price | 2025/08/27 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Royalty Pharma plc is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Jason Matthew Gerberry | BofA Global Research |
| Geoffrey Meacham | Citigroup Inc |